Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia (Q38836461)
Jump to navigation
Jump to search
scientific article published on 24 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia |
scientific article published on 24 March 2017 |
Statements
1 reference
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia (English)
1 reference
Shizuya Yamashita
Koutaro Yokote
Eiichi Araki
Hideki Suganami
Shun Ishibashi
K-877 Study Group
24 March 2017
1 reference